Determining the effects of risperidal Consta in patients with psychotic disorders and incomplete adherence.

Trial Profile

Determining the effects of risperidal Consta in patients with psychotic disorders and incomplete adherence.

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Nov 2014

At a glance

  • Drugs Risperidone (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Mar 2012 Actual patient number (64) added as reported by ClinicalTrials.gov.
    • 01 Mar 2012 Actual end date (Apr 2006) added as reported by ClinicalTrials.gov.
    • 25 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top